Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 4/20 | 0.49 |
| ▸ | KIT | P10721 | 6/20 | 0.45 |
| ▸ | MAP2K4 | P45985 | 2/20 | 0.41 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.40 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | AXL | P30530 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1591382 | 0.81 | AXL (0.44) | KITATMAXL | |
| SCHEMBL28720335 | 0.81 | BRD4 (0.56) | BRD4KITCYP17A1 | |
| SCHEMBL29549112 | 0.81 | BRD4 (0.56) | BRD4KITCYP17A1 | |
| SCHEMBL25680643 | 0.79 | SCN9A (0.41) | BRD4ATMAXL | |
| SCHEMBL20442949 | 0.77 | BRD4 (0.65) | BRD4 | |
| SCHEMBL1555087 | 0.74 | AXL (0.50) | KITAXL | |
| SCHEMBL20782711 | 0.74 | KIT (0.64) | KITAXL | |
| SCHEMBL30446793 | 0.74 | KIT (0.64) | KITAXL | |
| SCHEMBL28830984 | 0.73 | BRD4 (0.53) | BRD4KITCYP17A1 | |
| SCHEMBL29845731 | 0.73 | BRD4 (0.53) | BRD4KITCYP17A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200291024-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | ABBVIE INC (US) | 2020-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200291024-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | ENPP1, ENPP3, STING1 | BRD4 959/4885KIT 4057/4885MAP2K4 4276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.